ciltacabtagene autoleucel,idecabtagene vicleucel
janssen,2seventy bio,bms
['carvykti', 'abecma', 'mmsm']
new data shows response to abecma might be predicted by previous therapy; carvykti is highly active when given to patients earlier in their journey (1-3 prior lines of therapy) #mmsm #asco22 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.